Reading Time: 5 minutes While we work hard for a cure, it is essential we support those living with MND now. Professor Chris McDermott, Professor of Translational Neurology at
Category: Clinical Trials
Reading Time: 10 minutes For the purposes of this blog, ALS should be taken to mean ALS/MND. In September 2020 we published a blog article discussing Dr Rick Bedlack’s
Reading Time: 5 minutes "New drug reduces risk of death by 50%"
You may have seen this type of headline in news articles reporting on the outcome of clinical trials. Reading this headline can lead people to believe a potential drug is highly beneficial and has a real impact. However, it is important to delve a little deeper into the meaning of ‘risk of death’, the raw data behind it, and how it should be considered alongside other outcome measures of a trial to fully determine how effective a drug might be.
Reading Time: 5 minutes Hi, my name is Avril Mc Tague. I am undertaking a Ph.D. at Trinity College, Dublin, Ireland as part of the Multidisciplinary Innovation and Research Advancing Neurological care in a Digital Age (MIRANDA) doctoral award programme. This is funded by the Health Research Board in Ireland. I was one of five symposium communication ambassadors at last year’s international symposium.
Reading Time: 6 minutes Over the past couple of years, the pace of MND research has continued to increase. In the last year alone, we saw an increase in
34th Symposium: Basel Causes and disease mechanisms Clinical Trials Events Genetic Research Healthcare Markers of Disease Progression MND Research Symposium Treatments
Reuniting the MND community at the 34th International Symposium on ALS/MND
Reading Time: 4 minutes After 3 years of online events, the MND research and healthcare community reunited in-person at the 34th International Symposium on ALS/MND in Basel, Switzerland! From
34th Symposium: Basel Causes and disease mechanisms Clinical Trials Genetic Research MND Research Symposium Treatments
Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2
Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme. To give you a teaser of what is to come, we are taking a closer look at the plenary speakers in the ALS-FTD sessions at the Symposium. In this blog, we explore the topics they will be presenting and find out a little more about the speakers.
34th Symposium: Basel Causes and disease mechanisms Clinical Trials Genetic Research Healthcare Markers of Disease Progression MND Research Models of MND Research we fund Symposium Treatments
Symposium Preview: Meet the Symposium Communications Ambassadors
Reading Time: 7 minutes Each year at the Symposium, there is a huge amount of research presented on a range of topics from across the globe. With the Symposium returning to an in-person event this year, we are keen to increase the number of updates we share for those not able to attend, including people living with and affected by MND.
To help us do this, we have launched a new Symposium Communications Ambassador Programme so we can bring more of the research from the Symposium to non-scientific audiences. This programme was open for applications from early career researchers working in MND, who were interested in helping us shine a light on MND research happening across the world. This year we have 5 early career researchers taking part in the Programme, who will gain experience and new skills in communicating research to different audiences. Before, during and after the Symposium our Ambassador’s will be helping us to share the latest research with the MND community.
34th Symposium: Basel Causes and disease mechanisms Clinical Trials Events Genetic Research Markers of Disease Progression MND Research Symposium
Symposium Preview: Meet the ALS/MND Plenary Speakers…Part 2
Reading Time: 7 minutes Each year we invite plenary speakers who are experts in their fields to provide an overview on topics across MND research and clinical practice. This year we have 14 plenary speakers talking about ALS/MND who will discuss a wide range of topics from genetics to tissue biomarkers to improving clinical practice. In this second blog we will be taking a closer look at some of our plenary speakers this year and sharing more about the topics they will be discussing.